Synonym
Chlorphenoxamine; BRN2057618; BRN-2057618; BRN 2057618
IUPAC/Chemical Name
Ethanamine, 2-(1-(4-chlorophenyl)-1-phenylethoxy)-N,N-dimethyl-
InChi Key
KKHPNPMTPORSQE-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3
SMILES Code
CC(C1=CC=CC=C1)(C2=CC=C(Cl)C=C2)OCCN(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
303.83
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: ULDALL PR, WALTON JN, NEWELL DJ. Chlorphenoxamine hydrochloride in parkinsonism. A controlled trial. Br Med J. 1961 Jun 10;1(5240):1649-52. doi: 10.1136/bmj.1.5240.1649. PMID: 13779077; PMCID: PMC1954253.
2: KERLEY TL, RICHARDS AB, BEGLEY RW, ABREU BE, WEAVER LC. Anticonvulsant and antitremor effects of chlorphenoxamine. J Pharmacol Exp Ther. 1961 Jun;132:360-5. PMID: 13752621.
3: Dinç E, Palabiyik IM, Ustündağ O, Yurtsever F, Onur F. Simultaneous spectrophotometric determination of chlorphenoxamine hydrochloride and caffeine in a pharmaceutical preparation using first derivative of the ratio spectra and chemometric methods. J Pharm Biomed Anal. 2002 May 15;28(3-4):591-600. doi: 10.1016/s0731-7085(01)00694-x. PMID: 12008138.
4: KERLEY TL, NEWBERNE JW, BRINKMAN DC, WEAVER LC. The acute and chronic toxicities of chlorphenoxamine. Toxicol Appl Pharmacol. 1962 Sep;4:638-49. doi: 10.1016/0041-008x(62)90091-1. PMID: 14455272.
5: DOSHAY LJ, CONSTABLE K. Treatment of paralysis agitans with chlorphenoxamine hydrochloride. J Am Med Assoc. 1959 May 2;170(1):37-41. doi: 10.1001/jama.1959.03010010039008. PMID: 13640980.
6: Köppel C, Tenczer J, Arndt I, Ibe K. Urinary metabolism of chlorphenoxamine in man. Arzneimittelforschung. 1987 Sep;37(9):1062-4. PMID: 2893627.
7: Strang RR. A clinical evaluation of chlorphenoxamine with caffeine in the treatment of Parkinson's disease, including a comparison with methixene. J Clin Pharmacol J New Drugs. 1967 Jul-Aug;7(4):214-20. doi: 10.1002/j.1552-4604.1967.tb00050.x. PMID: 5340692.
8: Kelani KM. Simultaneous determination of caffeine, 8-chlorotheophylline, and chlorphenoxamine hydrochloride in ternary mixtures by ratio-spectra zero- crossing first-derivative spectrophotometric and chemometric methods. J AOAC Int. 2005 Jul-Aug;88(4):1126-34. PMID: 16152931.
9: MAGEE KR, CURRIER RD. Treatment of Parkinson's disease with chlorphenoxamine. J Mich State Med Soc. 1960 Sep;59:1364-5. PMID: 13765186.
10: BAZEX A, DUPRE A, CHRISTOL B. [Trial treatment of urticaria with chlorphenoxamine]. Clinique (Paris). 1963 Jul-Aug;58:447-50. French. PMID: 13967113.
